Jump Financial LLC Has $2.95 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Jump Financial LLC raised its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 64.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 114,902 shares of the company’s stock after acquiring an additional 45,035 shares during the period. Jump Financial LLC’s holdings in IDEAYA Biosciences were worth $2,953,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the business. R Squared Ltd bought a new stake in IDEAYA Biosciences during the 4th quarter worth approximately $35,000. Daiwa Securities Group Inc. raised its holdings in shares of IDEAYA Biosciences by 44.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company’s stock worth $72,000 after acquiring an additional 853 shares during the period. KBC Group NV lifted its position in IDEAYA Biosciences by 84.6% in the 4th quarter. KBC Group NV now owns 4,197 shares of the company’s stock valued at $108,000 after acquiring an additional 1,923 shares in the last quarter. Cibc World Markets Corp acquired a new position in IDEAYA Biosciences in the 4th quarter worth $203,000. Finally, XTX Topco Ltd acquired a new stake in shares of IDEAYA Biosciences in the 3rd quarter valued at about $245,000. 98.29% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have commented on IDYA. Stephens restated an “overweight” rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $61.00 price target on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IDEAYA Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $53.58.

IDEAYA Biosciences Price Performance

NASDAQ IDYA opened at $17.08 on Friday. IDEAYA Biosciences, Inc. has a fifty-two week low of $13.45 and a fifty-two week high of $44.42. The business has a fifty day moving average price of $18.32 and a two-hundred day moving average price of $23.95. The stock has a market capitalization of $1.50 billion, a PE ratio of -5.18 and a beta of 0.51.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The company had revenue of $7.00 million during the quarter, compared to analyst estimates of $7.00 million. As a group, sell-side analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.